TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium (Caputo et al 2008; Schroeder et al 2008; Yang et al 2008). It is now clinically established that promoting anion secretion in the airway leads to enhanced mucus clearance and reduced exacerbation frequency in CF patients and as such TMEM16A represents an important target for the next generation of mucokinetics. Importantly, positive regulators of TMEM16A function will be expected to be of benefit in all CF patients, irrespective of their CFTR mutational status.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical OfficerFebruary 10, 2020 - 9:00 am
- Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patientsJanuary 8, 2020 - 10:16 am
- TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019November 7, 2019 - 5:32 pm
- EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019November 7, 2019 - 5:30 pm
Follow Us On Twitter
#Lungdisease affects 1 in 5 people in the UK. That means you probably know someone whose life could be changed by taking @lunguk's breath test. Let's encourage people to love their lungs and raise awareness of lung conditions this #BreatheEasyWeek: https://bit.ly/3dmLtc5